Sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer: Phase III trial

Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or survival after a median five years of follow-up,…

Continue Reading

News Source: medicalxpress.com